Skip to main content

Trends in Healthcare Utilization During the COVID-19 Pandemic: A Propensity Score Matched and Stratified Analysis

    Basic Details
    Date Posted
    Status
    Complete
    Medical Product
    ACE inhibitors
    beta blockers
    Health Outcome(s)
    angioedema
    Description

    This analysis assessed the risk of angioedema following initiation of treatment with angiotensin converting enzyme (ACE) inhibitors or beta blockers using data from 2018 to 2022 in the Merative™ MarketScan® Research Databases. To estimate changes in healthcare utilization throughout the pandemic, we studied three time periods, resulting in three reports: Report 1: pre-pandemic (2018 and 2019), Report 2: mix (2019 and 2020), and Report 3: pandemic (2020 to 2022). A follow up analysis used one overall time period and was conducted in the Sentinel Distributed Database (SDD). 

    The study period includes data from May 22, 2018 to April 1, 2022. We ran this query against Merative™ MarketScan® Research Databases on September 13, 2023.

    The analytic package associated with this analysis can be found externally in Sentinel's Git Repository located here. The Git Repository serves as Sentinel's version control tracking system for analytic packages and technical documentation.

    Additional Details
    FDA Center
    CDER
    Time Period
    May 22, 2018 - April 1, 2022
    Analysis Type
    Retrospective Inferential
    Population / Cohort
    Individuals 18 years of age and older
    Data Sources
    Merative™ MarketScan® Research Databases